Advertisement

Der Kardiologe

, Volume 4, Issue 3, pp 189–207 | Cite as

Diagnostik und Therapie der pulmonalen Hypertonie

Europäische Leitlinien 2009
  • M.M. HoeperEmail author
  • H.A. Ghofrani
  • M. Gorenflo
  • E. Grünig
  • S. Rosenkranz
  • D. Schranz
Leitlinien

Vorbemerkung

Die ersten deutschen Leitlinien zur Pulmonalen Hypertonie sind 2006 erschienen [1, 2]. Diese lehnten sich an die 2004 veröffentlichten Leitlinien der European Society of Cardiology an [3]. Im August 2009 wurden die aktualisierten Europäischen Leitlinien zur Pulmonalen Hypertonie publiziert, die erstmalig gemeinsam von der European Society of Cardiology (ESC) und der European Respiratory Society (ERS) erstellt wurden [4, 5]. Die Deutsche Gesellschaft für Kardiologie (DGK) übernimmt seit einigen Jahren die von der ESC herausgegebenen Leitlinien. Eigene Leitlinien werden von der DGK nicht mehr erstellt. Auch die Arbeitsgruppen Pulmonale Hypertonie der Deutschen Gesellschaften für Pneumologie (DGP) und Pädiatrische Kardiologie (DGPK) haben vereinbart, in Zukunft keine neuen deutschen Leitlinien zur pulmonalen Hypertonie zu erstellen. Gemeinsam haben die jeweiligen Arbeitsgruppen Pulmonale Hypertonie die Aufgabe übernommen, die ESC/ERS-Leitlinien in Kurzform zusammenzufassen...

Diagnosis and treatment of pulmonary hypertension

2009 European guidelines

Notes

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Honorare für Vorträge und/oder Beratertätigkeiten: Actelion, Bayer, Gilead, GSK, Lilly, Pfizer.

Literatur

  1. 1.
    Olschewski H, Hoeper MM, Borst MM et al (2006) Diagnosis and therapy of chronic pulmonary hypertension. Pneumologie 60(12):749–771CrossRefPubMedGoogle Scholar
  2. 2.
    Olschewski H, Hoeper MM, Borst MM et al (2007) Diagnostik und Therapie der chronischen pulmonalen Hypertonie. Clin Res Cardiol 96(5):301–330CrossRefPubMedGoogle Scholar
  3. 3.
    Galie N, Torbicki A, Barst R et al (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25(24):2243–2278CrossRefPubMedGoogle Scholar
  4. 4.
    Galie N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 34(6):1219–1263CrossRefPubMedGoogle Scholar
  5. 5.
    Galie N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30(20):2493–2537CrossRefPubMedGoogle Scholar
  6. 6.
    Kovacs G, Berghold A, Scheidl S, Olschewski H (2009) Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 34(4):888–894CrossRefPubMedGoogle Scholar
  7. 7.
    Badesch DB, Champion HC, Sanchez MA et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl 1):S55–S66CrossRefPubMedGoogle Scholar
  8. 8.
    Rich S, Dantzker DR, Ayres SM et al (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107(2):216–223PubMedGoogle Scholar
  9. 9.
    Tongers J, Schwerdtfeger B, Klein G et al (2007) Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 153(1):127–132CrossRefPubMedGoogle Scholar
  10. 10.
    Hoeper MM, Pletz MW, Golpon H, Welte T (2007) Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 29(5):944–950CrossRefPubMedGoogle Scholar
  11. 11.
    Fisher MR, Forfia PR, Chamera E (2009) Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 179(7):615–621CrossRefPubMedGoogle Scholar
  12. 12.
    Arcasoy SM, Christie JD, Ferrari VA et al (2003) Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 167(5):735–740CrossRefPubMedGoogle Scholar
  13. 13.
    Fisher MR, Criner GJ, Fishman AP et al (2007) Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 30(5):914–921CrossRefPubMedGoogle Scholar
  14. 14.
    Tunariu N, Gibbs SJ, Win Z et al (2007) Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 48(5):680–684CrossRefPubMedGoogle Scholar
  15. 15.
    Resten A, Maitre S, Humbert M et al (2004) Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 183(1):65–70PubMedGoogle Scholar
  16. 16.
    Reichelt A, Hoeper MM, Galanski M, Keberle M (2009) Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography. Eur J Radiol 71(1):49–54CrossRefPubMedGoogle Scholar
  17. 17.
    Hoeper MM, Lee SH, Voswinckel R et al (2006) Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 48(12):2546–2552CrossRefPubMedGoogle Scholar
  18. 18.
    Jing ZC, Jiang X, Han ZY et al (2009) Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 33(6):1354–1360CrossRefPubMedGoogle Scholar
  19. 19.
    Sitbon O, Humbert M, Jais X et al (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111(23):3105–3111CrossRefPubMedGoogle Scholar
  20. 20.
    Galie N, Manes A, Negro L et al (2009) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30(4):394–403CrossRefPubMedGoogle Scholar
  21. 21.
    Mereles D, Ehlken N, Kreuscher S et al (2006) Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 114(14):1482–1489CrossRefPubMedGoogle Scholar
  22. 22.
    Man FS de, Handoko ML, Groepenhoff H et al (2009) Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 34(3):669–675CrossRefPubMedGoogle Scholar
  23. 23.
    Dupuis J, Hoeper MM (2008) Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 31:407–414CrossRefPubMedGoogle Scholar
  24. 24.
    Wilkins MR, Wharton J, Grimminger F, Ghofrani HA (2008) Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 32(1):198–209CrossRefPubMedGoogle Scholar
  25. 25.
    Olschewski H, Gomberg-Maitland M (2008) Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 31:801–901Google Scholar
  26. 26.
    Barst RJ, Rubin LJ, Long WA et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334(5):296–302CrossRefPubMedGoogle Scholar
  27. 27.
    Barst RJ, Langleben D, Frost A et al (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169(4):441–447CrossRefPubMedGoogle Scholar
  28. 28.
    Barst RJ, Langleben D, Badesch D et al (2006) Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47(10):2049–2056CrossRefPubMedGoogle Scholar
  29. 29.
    Galie N, Brundage BH, Ghofrani HA et al (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22):2894–2903CrossRefPubMedGoogle Scholar
  30. 30.
    Galie N, Olschewski H, Oudiz RJ et al (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117(23):3010–3019CrossRefPubMedGoogle Scholar
  31. 31.
    Galie N, Rubin L, Hoeper M et al (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630):2093–2100CrossRefPubMedGoogle Scholar
  32. 32.
    Galie N, Beghetti M, Gatzoulis MA et al (2006) Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114(1):48–54CrossRefPubMedGoogle Scholar
  33. 33.
    Galie N, Ghofrani HA, Torbicki A et al (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353(20):2148–2157CrossRefPubMedGoogle Scholar
  34. 34.
    Rubin LJ, Badesch DB, Barst RJ et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346(12):896–903CrossRefPubMedGoogle Scholar
  35. 35.
    Channick RN, Simonneau G, Sitbon O et al (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358(9288):1119–1123CrossRefPubMedGoogle Scholar
  36. 36.
    Simonneau G, Rubin LJ, Galie N et al (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149(8):521–530PubMedGoogle Scholar
  37. 37.
    Simonneau G, Barst RJ, Galie N et al (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165(6):800–804PubMedGoogle Scholar
  38. 38.
    Olschewski H, Simonneau G, Galie N et al (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347(5):322–329CrossRefPubMedGoogle Scholar
  39. 39.
    Oudiz RJ, Galie N, Olschewski H et al (2009) Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 54(21):1971–1981CrossRefPubMedGoogle Scholar
  40. 40.
    Hoeper MM, Gall H, Seyfarth HJ et al (2009) Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 34(1):132–137CrossRefPubMedGoogle Scholar
  41. 41.
    McLaughlin VV, Oudiz RJ, Frost A et al (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174(11):1257–1263CrossRefPubMedGoogle Scholar
  42. 42.
    Hoeper MM, Markevych I, Spiekerkoetter E et al (2005) Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26(5):858–863CrossRefPubMedGoogle Scholar
  43. 43.
    Mukerjee D, St George D, Coleiro B et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62(11):1088–1093CrossRefPubMedGoogle Scholar
  44. 44.
    Bull TM, Fagan KA, Badesch DB (2005) Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 31(3):451–464, viCrossRefPubMedGoogle Scholar
  45. 45.
    Hoeper MM, Seyfarth HJ, Hoeffken G et al (2007) Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 30(6):1096–1102CrossRefPubMedGoogle Scholar
  46. 46.
    Reichenberger F, Voswinckel R, Steveling E et al (2006) Sildenafil treatment for portopulmonary hypertension. Eur Respir J 28(3):563–567CrossRefPubMedGoogle Scholar
  47. 47.
    Grannas G, Neipp M, Hoeper MM et al (2008) Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation 85(4):524–531CrossRefPubMedGoogle Scholar
  48. 48.
    Sitbon O, Lascoux-Combe C, Delfraissy JF et al (2008) Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 177(1):108–113CrossRefPubMedGoogle Scholar
  49. 49.
    Grigioni F, Potena L, Galie N et al (2006) Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant 25(10):1241–1246CrossRefPubMedGoogle Scholar
  50. 50.
    Califf RM, Adams KF, McKenna WJ et al (1997) A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134(1):44–54CrossRefPubMedGoogle Scholar
  51. 51.
    Packer M, McMurray J, Massie BM et al (2005) Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 11(1):12–20CrossRefPubMedGoogle Scholar
  52. 52.
    Alaeddini J, Uber PA, Park MH et al (2004) Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 94(11):1475–1477CrossRefPubMedGoogle Scholar
  53. 53.
    Guazzi M, Samaja M, Arena R et al (2007) Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50(22):2136–2144CrossRefPubMedGoogle Scholar
  54. 54.
    Lewis GD, Shah R, Shahzad K et al (2007) Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116(14):1555–1562CrossRefPubMedGoogle Scholar
  55. 55.
    Lewis GD, Lachmann J, Camuso J et al (2007) Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115(1):59–66CrossRefPubMedGoogle Scholar
  56. 56.
    Behr J, Ryu JH (2008) Pulmonary hypertension in interstitial lung disease. Eur Respir J 31(6):1357–1367CrossRefPubMedGoogle Scholar
  57. 57.
    Chaouat A, Naeije R, Weitzenblum E (2008) Pulmonary hypertension in COPD. Eur Respir J 32(5):1371–1385CrossRefPubMedGoogle Scholar
  58. 58.
    Stolz D, Rasch H, Linka A et al (2008) A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 32(3):619–628CrossRefPubMedGoogle Scholar
  59. 59.
    Chaouat A, Bugnet AS, Kadaoui N et al (2005) Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172(2):189–194CrossRefPubMedGoogle Scholar
  60. 60.
    Thabut G, Dauriat G, Stern JB et al (2005) Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127(5):1531–1536CrossRefPubMedGoogle Scholar
  61. 61.
    Hoeper MM, Mayer E, Simonneau G, Rubin LJ (2006) Chronic thromboembolic pulmonary hypertension. Circulation 113(16):2011–2020CrossRefPubMedGoogle Scholar
  62. 62.
    Jais X, D’Armini AM, Jansa P et al (2008) Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 52(25):2127–2134CrossRefPubMedGoogle Scholar
  63. 63.
    Hughes RJ, Jais X, Bonderman D et al (2006) The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 28(1):138–143CrossRefPubMedGoogle Scholar
  64. 64.
    Hughes R, George P, Parameshwar J et al (2005) Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax 60(8):707CrossRefPubMedGoogle Scholar
  65. 65.
    Bonderman D, Nowotny R, Skoro-Sajer N et al (2005) Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128(4):2599–2603CrossRefPubMedGoogle Scholar
  66. 66.
    Hoeper MM, Kramm T, Wilkens H et al (2005) Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128(4):2363–2367CrossRefPubMedGoogle Scholar
  67. 67.
    Ghofrani HA, Schermuly RT, Rose F et al (2003) Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 167(8):1139–1141CrossRefPubMedGoogle Scholar
  68. 68.
    Reichenberger F, Voswinckel R, Enke B et al (2007) Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 30(5):922–927CrossRefPubMedGoogle Scholar
  69. 69.
    Bresser P, Fedullo PF, Auger WR et al (2004) Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 23(4):595–600CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • M.M. Hoeper
    • 1
    Email author
  • H.A. Ghofrani
    • 2
  • M. Gorenflo
    • 3
  • E. Grünig
    • 4
  • S. Rosenkranz
    • 5
  • D. Schranz
    • 6
  1. 1.Klinik für PneumologieMedizinische Hochschule HannoverHannoverDeutschland
  2. 2.Abteilung PneumologieJustus-Liebig-Universität GießenGießenDeutschland
  3. 3.Abteilung KinderkardiologieUZ Leuven Campus GasthuisbergLeuvenBelgien
  4. 4.Abteilung PneumologieThoraxklinik HeidelbergHeidelbergDeutschland
  5. 5.Abteilung KardiologieUniversitätsklinik KölnKölnDeutschland
  6. 6.Abteilung KinderkardiologieJustus-Liebig-Universität GießenGießenDeutschland

Personalised recommendations